Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial Cagrilintide Peptide Cagrilintide Medlabs Peptides Cagrilintide Research Peptide Information Peptpedia